Filtered By:
Drug: Lortab

This page shows you your search results in order of date.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Sodium-containing Acetaminophen Intake Increases the Risk of CVD and All-cause Mortality
Dr. Hoque Clinical question: Does the use of sodium-containing acetaminophen increase the risk of cardiovascular disease (CVD) and all-cause mortality in patients with and without a history of hypertension when compared to non-sodium-containing acetaminophen? Background: There is a common misconception that excess sodium intake comes primarily from dietary sources. The excipients of common over-the-counter medications such as some formulations of acetaminophen may contain significant amounts of sodium. For example, a 500-mg dose of soluble acetaminophen contains 390 mg of sodium, and a 500-mg dose of effervescent acetamin...
Source: The Hospitalist - October 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: In the Literature Source Type: research

Paracetamol: Four side effects when you go to the toilet - recent warning issued
PARACETAMOL, also known as acetaminophen, is a commonly used medicine that can help treat pain and reduce a high temperature. Recent research suggests that regular paracetamol use by people with high blood pressure could increase the risk of heart disease and stroke.
Source: Daily Express - Health - February 9, 2022 Category: Consumer Health News Source Type: news

Role of PI3K/Akt axis in mitigating hippocampal ischemia-reperfusion injury via CB1 receptor stimulation by paracetamol and FAAH inhibitor in rat
Neuropharmacology. 2021 Dec 27:108935. doi: 10.1016/j.neuropharm.2021.108935. Online ahead of print.ABSTRACTAIMS: Acetaminophen or paracetamol (PAR), the recommended antipyretic in COVID-19 and clinically used to alleviate stroke-associated hyperthermia interestingly activates cannabinoid receptor (CB1) through its AM404 metabolite, however, to date, no study reports the in vivo activation of PAR/AM404/CB1 axis in stroke. The current study deciphers the neuroprotective effect of PAR in cerebral ischemia/reperfusion (IR) rat model and unmasks its link with AM404/CB1/PI3K/Akt axis.MATERIALS AND METHODS: Animals were allocate...
Source: Neuropharmacology - December 30, 2021 Category: Drugs & Pharmacology Authors: Sherif S Abdel Mageed Ramy M Ammar Noha N Nassar Helmy Moawad Ahmed S Kamel Source Type: research

Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase
Conclusion: The fatal adverse events associated with the combined use of dabigatran and aspirin in elderly patients were mainly serious bleeding events, which often occurred within 1 month. Most of these cases had medication errors and most of the patients had multiple diseases, medications, or other conditions at the same time that increase the risk of bleeding. It is suggested that prescription of dabigatran and aspirin in elderly patients should go along with alertness for medication errors, care for correct dose or control of other bleeding risk factors, and the combined medication time should be as short as possible ...
Source: Frontiers in Pharmacology - December 22, 2021 Category: Drugs & Pharmacology Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis.
Authors: Akhter N, Ahmad S, Alzahrani FA, Dar SA, Wahid M, Haque S, Bhatia K, Sr Almalki S, Alharbi RA, Sindi AAA Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) uses Angiotensin- converting enzyme 2 (ACE2) receptors to infect host cells which may lead to coronavirus disease (COVID-19). Given the presence of ACE2 receptors in the brain and the critical role of the renin-angiotensin system (RAS) in brain functions, special attention to brain microcirculation and neuronal inflammation is warranted during COVID-19 treatment. Neurological complications reported among COVID-19 patients range from mi...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

A COVID-19 patient with intense burning pain
AbstractA woman in her forties with asthma and COPD was admitted to a general medical floor with respiratory symptoms, body aches, and anosmia. Reverse transcription polymerase chain reaction detected severe acute respiratory syndrome coronavirus-2. Admission labs, including biomarkers of the systemic immunological dysfunction seen in many cases of coronavirus disease 2019 (COVID-19), were within normal ranges. On the second day of admission, she developed neck and back pain that was constant, burning in quality, and exacerbated by light touch and heat. Wearing clothing caused pain and interfered with her sleep. The area w...
Source: Journal of NeuroVirology - August 9, 2020 Category: Neurology Source Type: research

Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
ConclusionsInducing normothermia with a novel transnasal TMD appears to be safe, feasible and not associated with significant shivering. A multicenter trial testing the ability of the CoolStat to maintain normothermia for 24  h is currently underway.
Source: Neurocritical Care - July 13, 2020 Category: Neurology Source Type: research

A Case of Fabry Disease Presenting with Young Stroke and Fever.
Authors: Wu LC, Chiang CT, Lee KF Abstract Although it is known that Fabry disease should be included in the differential diagnosis of young stroke and fever of unknown origin, it has not been reported in the literature of stroke with fever as the presentation of Fabry disease. This is relevant because stroke with fever may misguide the differential diagnosis. Here we present a young stroke patient with fever. DWI of brain MRI revealed acute multiple infarctions. Due to the fever, infectious and inflammatory origins such as infective endocarditis and autoimmune diseases were examined first. However, we could not id...
Source: Acta Neurologica Taiwanica - December 25, 2019 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

FDA Approves New Drug For Migraine Sufferers
(CNN) — The US Food and Drug Administration on Monday announced the approval of a drug called ubrogepant for the acute treatment of migraine, which could be a new option for people who can’t take or don’t respond to migraine medications currently on the market. The drug will be sold under the name Ubrelvy by the pharmaceutical company Allergan. It is considered effective for migraine with or without aura, referring to the sensory or visual disturbances that occur among roughly a third of migraine sufferers. “Ubrelvy represents an important new option for the acute treatment of migraine in adults, as...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston FDA Migraines Source Type: news

Continuous intravenous low-dose diclofenac sodium to control a central fever after ischemic stroke in the intensive care unit: a case report and review of the literature
ConclusionsWe observed that a low-dose diclofenac sodium infusion was effective in treating fever without systemic side effects. This treatment may be suggested as an alternative to conventional antipyretic drugs, but additional clinical trials are required.
Source: Journal of Medical Case Reports - December 17, 2019 Category: General Medicine Source Type: research

New Drug To Treat Migraines Shows Promise
(CNN) — A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours and more than 34% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to 14% and 27%, respectively, from the placebo. “Having ubrogepant as a potential new medication for the acute treatment of m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Migraines Source Type: news

Many take anticoagulants and OTC supplements, which poses risk
FINDINGSNearly 98% percent of people prescribed direct-acting oral anticoagulants such as apixaban also used  over-the-counter products. Of those, 33% took at least one such product that, in combination with the anticoagulants, could cause dangerous internal bleeding. People taking these medications largely lacked knowledge of some potentially serious interactions.BACKGROUNDDirect-acting oral anticoagulants are the drug of choice for stroke prevention in patients with atrial fibrillation, which occurs most frequently in older patients. Apixaban is one of the most frequently prescribed. However, most people prescribed apix...
Source: UCLA Newsroom: Health Sciences - October 31, 2019 Category: Universities & Medical Training Source Type: news